Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4559 - Tyrosine Kinase Inhibitors (TKI): Awareness of Drug-Drug Interaction


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP


Nuriye Ozdemir


Annals of Oncology (2017) 28 (suppl_5): v395-v402. 10.1093/annonc/mdx375


N. Ozdemir1, S. Toptas2, M.A.N. Sendur1, O. Yazici3, B. Öksüzoğlu4, K. Silay5, N. Zengin3

Author affiliations

  • 1 Department Of Medical Oncology, Ankara Yıldırım Beyazıt Universtiy Faculty of Medicine, 06300 - Ankara/TR
  • 2 Medical Oncology, Ankara Numune Education and Research Hospital, 06100 - Ankara/TR
  • 3 Medical Oncology, Ankara Numune Education and Research Hospital, 6100 - Ankara/TR
  • 4 Medical Oncology, Dr.abdurrahman yurtaslan ankara oncology training and research hospital, 6200 - Ankara/TR
  • 5 Department Of Geriatrics, Ankara Yıldırım Beyazıt Universtiy Faculty of Medicine, 06300 - Ankara/TR


Abstract 4559


Since TKI are metabolized with cytochrome P450 system which is a common pathway for drug-drug interactions. However, these interactions might be overlooked by clinicians. The aim of this study is to evaluate the drug-drug interactions in patients receiving TKI.


Between May 2007 and March 2015, the data of 265 patients receiving TKI for any reason were evaluated retrospectively. All prescribed medications (PMs) received during TKI therapy for 6 months period were noted and drug-drug interactions with TKI were evaluated. Additionally the nature of interaction was described as ‘increase or decrease in TKI level or cautious use of TKI recommended’. The interaction between TKI and PMs was checked from Up-To-Date web site or ''medscape.com/drug-interaction checker''.


In the study, 265 patients who are taking TKI were noted. 251 patients (94.8%) have been taking PMs additional to TKI. The median age was 56 year (17-87), most common diagnosis was gastrointestinal stromal tumor (27.5%) followed by kidney tumor (26.3%). Most common TKI has been used was Imatinib (21.9%) and Lapatinib (21.9%). The most common PM groups during 6 months period was non-steroidal anti inflammatory and acetaminophen (50.2%), proton pomp inhibitors (41.4%), antibiotics (33.1%), cardiovascular system drugs (33.5%) and narcotic analgesics (21.1%). The interaction rate between TKI and PMs was 54.2%. The nature of interaction was; decrease in TKI level in 39.7% of patients and increase in TKI level in 30.1% of patients. 77.1% of patients have been warned as cautious use of TKI due to increase risk of side effect. The side effect was emphasized as QT prolongation.


TKI drug interaction is usually overlooked by clinicians. Our study revealed that more than 90% of patients who are taking TKI are also prescribed another medication. There is a drug-drug interaction between TKI and prescribed medications in more than half of these patients. TKI-prescribed drug interaction has been caused decrease effectiveness of treatment and increase the rate of side effects and medical cost. The TKI –drug interaction risk might be decreased by increasing the knowledge of the physicians from other specialties about recent molecular treatments.

Clinical trial identification

Legal entity responsible for the study

Ankara Numune Education and Research Hospital




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.